PS-002 (Pharmasaga Co. Ltd.)

PS-002 is an investigational small molecule oral tablet being developed by Pharmasaga for the treatment of Type 1 Diabetes. Currently in Phase 2 clinical development, the drug is intended to address the underlying pathology of Type 1 Diabetes, potentially through the preservation or restoration of pancreatic beta-cell function. While the specific molecular target has not been publicly disclosed by the developer, PS-002 represents a novel oral approach to a disease traditionally managed with injectable insulin. It is part of Pharmasaga's pipeline of metabolic-focused therapies, which also includes candidates for Type 2 Diabetes and cancer.